Fulgent Genetics (FLGT) Soars 6.6%: Is Further Upside Left in the Stock?

Fulgent Genetics scored a strong price increase on investors' optimism surrounding its impending secondquarter 2024 financial results, which is slated to release on Aug 2 post the closing bell. The Zacks Consensus Estimate for the second quarter revenue indicate a 1.3% growth year over year. Furthermore, Precision Diagnostics, presently the largest growth driver in the company's laboratory services business, posted a 34% year-over-year revenue growth in the first quarter. While earnings and revenue growth e ...